Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) Shares Outstanding (Weighted Average): 2010-2025

Historic Shares Outstanding (Weighted Average) for Niagen Bioscience (NAGE) over the last 14 years, with Sep 2025 value amounting to $79.8 million.

  • Niagen Bioscience's Shares Outstanding (Weighted Average) rose 5.03% to $79.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $79.8 million, marking a year-over-year increase of 5.03%. This contributed to the annual value of $76.4 million for FY2024, which is 1.68% up from last year.
  • Niagen Bioscience's Shares Outstanding (Weighted Average) amounted to $79.8 million in Q3 2025, which was up 1.25% from $78.8 million recorded in Q2 2025.
  • Niagen Bioscience's Shares Outstanding (Weighted Average)'s 5-year high stood at $79.8 million during Q3 2025, with a 5-year trough of $66.7 million in Q1 2021.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $75.5 million (2024), whereas its average is $76.3 million.
  • Data for Niagen Bioscience's Shares Outstanding (Weighted Average) shows a peak YoY grew of 11.63% (in 2021) over the last 5 years.
  • Over the past 5 years, Niagen Bioscience's Shares Outstanding (Weighted Average) (Quarterly) stood at $68.3 million in 2021, then grew by 9.05% to $74.5 million in 2022, then grew by 0.88% to $75.1 million in 2023, then rose by 1.68% to $76.4 million in 2024, then climbed by 5.03% to $79.8 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $79.8 million for Q3 2025, versus $78.8 million for Q2 2025 and $77.8 million for Q1 2025.